Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Aclidinium/Formoterol on Nighttime Lung Function in COPD
NCT02429765Phase 4Completed
- Sponsor
- Queen's University
- Start
- Oct 2015
- Primary completion
- Aug 2018
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aclidinium bromide + formoterol in chronic obstructive pulmonary disease (COPD), sponsored by Queen's University. Started Oct 2015; status: completed.
02
Drugs
aclidinium bromide + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02429765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429765.